Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects

The document reviewed the use of solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) for drug delivery, highlighting their potential advantages over traditional systems. SLNs and NLCs improved drug stability, controlled release, and bioavailability, particularly for drugs with low aqueous solubility. They showed promise in enhancing oral bioavailability, targeting cancer cells, and treating skin conditions. However, challenges such as complex synthesis, potential toxicity, and limited clinical trials were noted. The review emphasized the need for further research to address these challenges and establish standardized safety assessments and regulatory frameworks. Despite their potential, SLNs/NLCs were not yet widely used in clinical settings, indicating that their market entry would take time.